LLY compared with AVBP: revenue, margins and what each company keeps, and the suppliers and customers both name

LLYELI Lilly & Co

Mkt capRevenueRevenue

AVBPArriVent BioPharma, Inc.

Mkt capRevenueRevenue

Compare

LLYELI Lilly & Co

AVBPArriVent BioPharma, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

LLY

3 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±5.1%▲+6.63%×1.29

Q2 FY26±6.2%▲+4.86%×0.79

Q1 FY26±5.3%▲+9.80%×1.85

Feb 4 '26±6.1%▲+10.33%×1.69

AVBP

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±16.3%▼−4.64%×0.28

May 12 '26±11.3%▼−0.17%×0.02

= impliedLLY realized, solidAVBP realized, hatchedOne scale, both sides: full bar = 26%× = |realized| ÷ impliedSource: market data

Q1 FY26

±25.8%

▼−7.21%

×0.28

Nov 10 '25±21.0%▲+3.08%×0.15

LLYELI Lilly & Co

1,373.45▲+0.64%

Mkt cap$1.2TRevenue$24.4BQ3 FY26Revenue$65.2BFY25

AVBPArriVent BioPharma, Inc.

12.24▲+0.10%

Regular sessionNov 6 '26

Mkt cap$582.2MRevenue—Revenue—

Compare

Regular sessionNov 6 '26

LLYELI Lilly & Co

AVBPArriVent BioPharma, Inc.

1,373.45▲+0.64%

Price

12.24▲+0.10%

$1.2T

Mkt cap

$582.2M

Q3 FY26$24.4B

Revenue

—

FY25$65.2B

Revenue

—

LLY1,373.45▲+0.64%vsAVBP12.24▲+0.10%Regular sessionNov 6 '26